Filings
Finds words inside filing documents. Searching Xenon Pharmaceuticals Inc.'s filings · 36 documents indexed.
7 documents · 8 matches
-
XENE Xenon Pharmaceuticals Inc. 10-K 2026-02-26
Item 8. Financial Statements and Supplementary Data
material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk2 matches in this document -
XENE Xenon Pharmaceuticals Inc. 10-Q 2026-11-09
Item 1A. Risk Factors
weak or flawed. An unfavorable outcome in such litigation or proceedings may expose us or any future strategic collaborators to loss of our proprietary position, expose us to significant liabilities, or require us to seek licenses that may not be available on commercially acceptable terms1 match in this document -
XENE Xenon Pharmaceuticals Inc. 10-Q 2026-08-06
Item 1A. Risk Factors
weak or flawed. An unfavorable outcome in such litigation or proceedings may expose us or any future strategic collaborators to loss of our proprietary position, expose us to significant liabilities, or require us to seek licenses that may not be available on commercially acceptable terms1 match in this document -
XENE Xenon Pharmaceuticals Inc. 10-Q 2026-05-07
Item 1A. Risk Factors
weak or flawed. An unfavorable outcome in such litigation or proceedings may expose us or any future strategic collaborators to loss of our proprietary position, expose us to significant liabilities, or require us to seek licenses that may not be available on commercially acceptable terms1 match in this document -
XENE Xenon Pharmaceuticals Inc. 10-Q 2025-11-03
Item 1A. Risk Factors
weak or flawed. An unfavorable outcome in such litigation or proceedings may expose us or any future strategic collaborators to loss of our proprietary position, expose us to significant liabilities, or require us to seek licenses that may not be available on commercially acceptable terms1 match in this document -
XENE Xenon Pharmaceuticals Inc. 10-Q 2025-08-11
Item 1A. Risk Factors
weak or flawed. An unfavorable outcome in such litigation or proceedings may expose us or any future strategic collaborators to loss of our proprietary position, expose us to significant liabilities, or require us to seek licenses that may not be available on commercially acceptable terms1 match in this document -
XENE Xenon Pharmaceuticals Inc. 10-Q 2025-05-12
Item 1A. Risk Factors
weak or flawed. An unfavorable outcome in such litigation or proceedings may expose us or any future strategic collaborators to loss of our proprietary position, expose us to significant liabilities, or require us to seek licenses that may not be available on commercially acceptable terms1 match in this document
Page 1 of 1 · 7 documents